Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04236479
PHASE1

Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)

Sponsor: Catherine Bollard

View on ClinicalTrials.gov

Summary

The proposed study will be a prospective, open-label, single-center, safety and feasibility phase 1 trial of allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery though cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life

Official title: Mesenchymal Stromal Cells Delivery Through Cardiopulmonary Bypass in Pediatric Cardiac Surgery

Key Details

Gender

All

Age Range

Any - 6 Months

Study Type

INTERVENTIONAL

Enrollment

17

Start Date

2020-07-29

Completion Date

2026-09

Last Updated

2025-04-29

Healthy Volunteers

No

Interventions

BIOLOGICAL

BM-MSC

Allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery through cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing a two-ventricle repair within the first six months of life.

Locations (1)

Children's National Health System

Washington D.C., District of Columbia, United States